Found: 23
Select item for more details and to access through your institution.
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 6, p. 1571, doi. 10.1007/s40120-024-00664-z
- By:
- Publication type:
- Article
Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 6, p. 1541, doi. 10.1007/s40120-024-00658-x
- By:
- Publication type:
- Article
BACE1 as a Potential Biomarker for Alzheimer's Disease.
- Published in:
- Journal of Alzheimer's Disease, 2011, v. 24, n. S2, p. 53
- By:
- Publication type:
- Article
BACE1 as a Potential Biomarker for Alzheimer's Disease.
- Published in:
- Journal of Alzheimer's Disease, 2011, v. 23, n. S1, p. 53, doi. 10.3233/JAD-2011-110017
- By:
- Publication type:
- Article
BACE1 as a potential biomarker for Alzheimer's disease.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Mclena‐1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease; Interim progress.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.072340
- By:
- Publication type:
- Article
Does the presence of type II Diabetes affect cognitive decline in Alzheimer's Disease Dementia?
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 7, p. 1, doi. 10.1002/alz.059710
- By:
- Publication type:
- Article
Plasma biomarkers combined with UPDRS and MoCA for differential assessments of amnestic cognitive impairment (aMCI), Parkinson's disease (PD+PDD) and dementia with Lewy body (DLB): A pilot study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.059716
- By:
- Publication type:
- Article
Nevada exploratory Alzheimer's disease research center: Advancing dementia care in rural communities.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051081
- By:
- Publication type:
- Article
Is Type 2 diabetes mellitus associated with an increased pathological burden in clinically and pathologically diagnosed Alzheimer's dementia?: Human neuropathology/clinico‐pathologic correlations.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.040048
- By:
- Publication type:
- Article
P4‐016: MCLENA‐1: A PHASE II CLINICAL TRIAL FOR THE ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LENALIDOMIDE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE; TRIAL DESIGN AND RATIONALE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1279, doi. 10.1016/j.jalz.2019.06.3675
- By:
- Publication type:
- Article
Preclinical testing of lenalidomide as anti-amyloid treatment for Alzheimer's disease
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Are platelet BACE1 levels altered in Alzheimer's disease patients?
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Alzheimer's disease subjects carrying the APOE4 allele have lower brain BACE1 levels than APOE3 carriers
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Critical Appraisal of Amyloid Lowering Agents in AD.
- Published in:
- Current Neurology & Neuroscience Reports, 2021, v. 21, n. 8, p. 1, doi. 10.1007/s11910-021-01125-y
- By:
- Publication type:
- Article
Is diabetes associated with increased pathological burden in Alzheimer's disease?
- Published in:
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021, v. 13, n. 1, p. 1, doi. 10.1002/dad2.12248
- By:
- Publication type:
- Article
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer's Disease.
- Published in:
- Biomedicines, 2024, v. 12, n. 1, p. 99, doi. 10.3390/biomedicines12010099
- By:
- Publication type:
- Article
Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia.
- Published in:
- Journal of Experimental Pharmacology, 2022, v. 14, p. 331, doi. 10.2147/JEP.S265626
- By:
- Publication type:
- Article
The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress.
- Published in:
- Aging & Disease, 2022, v. 13, n. 1, p. 37, doi. 10.14336/AD.2021.0529
- By:
- Publication type:
- Article
Platelet BACE1 levels as a possible biomarker for Alzheimer's disease.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 4, p. 975, doi. 10.1007/s40120-024-00614-9
- By:
- Publication type:
- Article
MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
- Published in:
- Open Access Journal of Clinical Trials, 2020, v. 12, p. 1, doi. 10.2147/OAJCT.S221914
- By:
- Publication type:
- Article
Is otospiralin inner ear specific? Evidence for its expression in mouse brain
- Published in:
- International Journal of Developmental Neuroscience, 2009, v. 27, n. 1, p. 87, doi. 10.1016/j.ijdevneu.2008.09.001
- By:
- Publication type:
- Article